Ocular Inflammation and Pain

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Formosa Pharmaceuticals
1 program
1
APP13007, 0.05%Phase 31 trial
Active Trials
NCT04739709Completed378Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Formosa PharmaceuticalsAPP13007, 0.05%

Clinical Trials (1)

Total enrollment: 378 patients across 1 trials

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery

Start: Jan 2021Est. completion: Mar 2022378 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space